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Abstract:
Background:
We compared daily pain, home analgesic use, and utilization, among
ambulatory adults in the randomized Multicenter Study of Hydroxyurea in Sickle
Cell Anemia (MSH).

We related the fetal hemoglobin (HbF) response to

hydroxyurea to these response variables.

Methods
MSH enrollees rated daily their sickle cell pain intensity (0-9), whether or
not they took analgesics, and whether they visited any medical facility for pain.
Diaries were collected biweekly at study visits, and intensity was collapsed into
single interval ratings. The interval proportions of days of analgesic use and
medical visits for pain were also calculated. Group comparisons were made by

intention to treat as well as by HbF change levels from baseline to 2 years of
treatment (placebo, and low, medium, high, or very high response),.

Results
A total of 134 (44.8%) enrollees completed two years of follow-up. Pain
intensity correlated with analgesic use (r=.83, p.>0001) and utilization (r=.50,
p<.0001). Pain intensity was lower for patients on hydroxyurea (2.51 ± 0.062 vs.
2.82 ± 0.063 placebo, F(1,270)=11.65, p=.0007). The difference, appeared early
and was sustained, though small, appeared early and was sustained. Analgesic
use and utilization were also slightly lower (analgesic use: F(1,270)=11.97,
p=.0006; utilization: F(1,270)=32.0, p<.0001). Each were each statistically
significantly lower among hydroxyurea patients with higher HbF treatment
responses to hydroxyurea.

Conclusions
Hydroxyurea use led to a small, statistically significant lightly reduced
reduction in daily pain, analgesic use, and utilization in adults in MSH, in contrast
to its corroborating its previously shown dramatic larger reductions in crisiscrises
and mortality. The degree of daily symptomatic reduction was related to the size
of the HbF treatment response, further confirming HbF response as a useful
laboratory correlate.
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Introduction
Pain is the most prominent feature of sickle cell disease (SCD). Pain is
responsible for the majority of SCD medical visits (utilization).i The often episodic
nature of sickle cell pain and the sometimes infrequent utilization have led
caregivers to use the term “crisis” to describe utilization provoked by pain.
Higher-utilizing adults are at higher risk of death, so measuring crises has clinical
meaning.ii
However, most SCD pain, even “crisis” pain, is managed at home, without
utilization, based on results of longitudinal epidemiologic studies. iii iv v vi vii
Hydroxyurea is the only Food and Drug Administration-approved remittive
agent for homozygous SCD (HbSS, sickle cell anemia). Its benefit was tested in

the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH).viii

This

randomized, double-blind placebo controlled study clearly showed that
hydroxyurea reduced the rate of painful crises in adult sickle cell anemia patients
with at least three painful crises per year.ix
In practice, differences in crises, which may occur infrequently for many
patients, may be subtle and hard to gauge. When clinicians prescribe
hydroxyurea to individual patients, and when patients are deciding whether to
continue to take this lifelong treatment, they may be more interested in the
relationship of hydroxyurea therapy to pain managed at home and to home
analgesic use. It is unclear whether the reduction in crises found in the MSH was
paralleled by a similar reduction in daily pain or analgesic use. It is also unclear
whether any possible daily pain or analgesic use reduction predated the
reduction in crises.
Although earlier results questioned its value,x

xi

An later publications

confirmed an increase in fetal hemoglobin (HbF) level ais one common and likely
important laboratory measure of responsiveness to hydroxyurea in SCD.xii
xvi

xiii xiv xv

Independent of other predictors, low levels of fetal hemoglobin were

associated with higher mortality in the Cooperative Study of Sickle Cell
Disease.xvii In the MSH trial, the proportion of red cells containing HbF (F cells)
rose between 8 and 24 weeks among patients on hydroxyurea vs. placebo.9
However,

subtle and early

RBC and reticulocyte indices,

markers of response to HU

included

changes in

most of the

first detected 10 weeks after starting HU and before the

increase in Hb F levels.xviii
In the MSH nonrandomized follow-up phase.. survival at 9 years was
improved among patients showing increasing HbF response to HU,xix Further, at
17.5 years, the mortality rate was increasingly lower among groups of patients
who reported taking HU for increasingly larger proportions of the folllowup period,
up to ≥ 15 years,, although stroke, organ dysfunction, and infection were similar
in all groups. Survival curves demonstrated a significant reduction in deaths with
long-term HU exposure.xx Responders to HU used analgesics on fewer days,

and their average length of hospital stay was about two days less.xxi MSH
Patients on HU demonstrated a trend for more consistent employment, even
though all MSH patients had moderate to severe disease.xxii
Still, the relationship between the HbF response to hydroxyurea and the
daily pain and analgesic use response is unknown.
The MSH dataset afforded us the ability to examine the association
between hydroxyurea treatment and daily pain of SCD, specifically measured as
daily pain intensity ratings, daily analgesic use, and daily pain-related utilization.
We also assessed how the overall and temporal effects of hydroxyurea on each
of these daily symptomatic response variables related to the HbF response.

Methods
The MSH sample
The MSH procedures and study inclusion and exclusion criteria have been
previously published.8 Briefly, to be eligible for the MSH study, patients had to
be at least 18 years old and have sickle cell anemia. They also had to have at
least 3 reported painful crises in the year prior to entry into the study. A total of
299 patients were enrolled from 21 sites (20 in the U.S. and 1 in Canada).
Patients were overwhelmingly (95%) African-American.

There were no

significant differences between the hydroxyurea and placebo groups in terms of
sex, race, age, or blood counts.9

Analysis of detailed demographic

characteristics of this sample are beyond the bounds of this manuscript, but
briefly, the sample was equally male and female, with an average age of 30
years at study entry baseline. While nearly half had completed at least some
college, most were unemployed (61%). Table 1 summarizes demographic
characteristics of the MSH participants.

Study procedures, measures
Once enrolled, patients had biweekly study-related visits throughout the
duration of the study. As noted above, frequency of painful crises (defined as
medical facility visits with no apparent cause other than an exacerbation of SCD

pain, lasting ≥ 4 hours, for which the patient was treated with opioid or
nonsteroidal antiinflammatory drugs) was the primary endpoint of the study. But
aside from the frequency of painful crises, several other pain-related measures
were collected and served as the outcomes of interest in this study.
While out of the hospital, at each biweekly clinic visit, patients returned a
pain diary in which they rated their daily pain intensity on a 0-9 scale; indicated
whether or not analgesics were taken that day; and indicated whether any
medical facility was visited for pain-related reasons (this included both
unscheduled acute-care contacts such as emergency department use or clinic
visits, and in-patient hospitalization). Daily pain intensity ratings from each diary
were averaged to provide a single average pain intensity rating for each 2-week
period (pain intensity). Almost always, ratings represented 14 days of diaries,
because diary recordings of the severity of pain, use of analgesics, and visits to
medical facilities were reviewed every 2 weeks at a clinic visit by members of the
clinic staff.

When (rarely) data were missing from one or more days, pain

intensity was calculated from the reduced number of days. The measure of
analgesic usage (analgesic use) was the proportion of days with reported
analgesic use in each diary, calculated by dividing the number of days with
analgesic use by the total number of days. As with pain intensity, when data
were missing from one or more days analgesic use was calculated from the
available data.

The measure of pain-related medical visits (utilization) was

calculated in the same way as analgesic use; the number of days with visits was
divided by the total number of days in each diary. Thus, values for pain intensity
ranged from 0 to 9, and values for analgesic use and utilization ranged from 0 to
1.
In addition to demographic characteristics of patients, a measure of
health-related limitations on physical activity, obtained once at the beginning of
the study, was also included as an adjustment variable. This score was based
on a multi-item questionnaire on which participants indicated whether or not their
health limited their participation in ten different activities ‘a lot,’ ‘a little,’ or ‘not at

all.’ Because some of these items were very similar except for how strenuous
they were (e.g., climbing several flights of stairs versus one flight of stairs), the
final score was based on six different items that included only the most strenuous
of closely related activities, with higher scores indicating more health limitations
on physical activities.

Drug assignment and drug HbF response
Drug assignment at study entry (hydroxyurea versus placebo) was a key
predictor of interest for pain outcomes.

But in prior analyses, hydroxyurea

recipients were also coded into four response groups based on quartiles of HbF
response to treatment: the change in HbF levels from baseline to the 2-year
measurement.12 HbF response levels were defined as ‘low’ (a decrease of 0.3 or
more in %HbF; n=34), ‘medium’ (a decrease of less than 0.3 to an increase of
1.7 in %HbF; n=38), ‘high’ (an increase of 1.7 to 6.5 in %HbF; n=36), and ‘very
high’ (an increase greater than 6.5 in %HbF; n=35). For additional exploration of
outcomes, a second HbF response variable was coded that collapsed the low
and medium groups into a single ‘lower’ response group (n=69), and the high and
very high groups into a single ‘higher’ response group (n=68).

Both HbF

response measures were also coded ordinally (1-4 for the four-group
categorization and 1-2 for the two-group categorization, with the placebo group
coded as 0), to allow testing of linear associations between daily symptomatic
response measures and HbF response.

Statistical methods
To examine the magnitude of association between pain intensity,
analgesic use, and utilization, overall average values were calculated across all
pain diaries for each subject, and then used to obtain Pearson correlations
between each variable.
Mixed models regression analyses (PROC MIXED in SAS 9.1.3) were
used to model pain intensity, analgesic use, and utilization.

Mixed modeling

allowed for inclusion of both between- and within-subject measures, and both
fixed and random factors, in a single model. The models of each of the three

daily symptomatic response measures were run three times, substituting
treatment assignment, the five-group HbF response classification, and the threegroup HbF response classification as the predictors of interest.
Patient age and sex were included in the models as adjustment variables.
Variables for drug assignment (hydroxyurea versus placebo), age and sex were
appropriately centered; study site was dummy-coded and centered also, to
control for possible differences between sites.

Personal income was also

included (preliminary analyses showed a stronger correlation of pain measures
with personal income than with household income). Finally, the health limitations
variable was also included. A random statement allowed for individual subject
variation in intercepts and slopes, and a repeated statement controlled for
repeated measures on the same subject. The matrix structure for correlations
between visits was defined as 1st-order autoregressive. Preliminary analyses
indicated that other matrix structures (such as compound symmetry) resulted in
an inferior fit for the model.

Results
Although originally intended to last 24 months for all participants, the trial
was stopped early because of the beneficial effects observed. Only 134 of the
299 patients completed the full two years of follow-up, and the mean follow-up
was 21 months.
Pain intensity and analgesic use were highly correlated, r=.83, p.<.0001.
Correlations of both of these measures with utilization were lower, but still highly
significant (r=.50, p<.0001, for pain intensity and r=.48, p<.0001 for analgesic
use).
Table 2 shows least squares means estimates and standard errors for
each of the three daily symptomatic response variables from each of three
models, and the statistical significance of all pairwise group comparisons. The
first set of models tested treatment assignment (hydroxyurea and placebo) as a
predictor of pain intensity, analgesic use, and utilization. We found significant
differences for all three variables. Hydroxyurea patients had lower pain intensity

over time, F(1,270)=11.65, p=.0007; lower analgesic use, F(1,270)=11.97,
p=.0006; and lower utilization, F(1,270)=32.0, p<.0001. Figure 1 shows pain
intensity through 21 months (the average follow-up period) for the hydroxyurea
and placebo groups.
The second set of models tested the five-group hydroxyurea HbF
response classification variable (four levels of HbF response plus the placebo
group). HbF response was modeled both as an ordinal variable (using the 0 to 5
scoring described above) to test linear trends, and as a categorical variable to
obtain least squares means estimates.

As a predictor of pain intensity, the

overall HbF response to hydroxyurea was significant, F(1,264)=33.64, p<.0001.
Pairwise comparisons of least squares means between all groups indicated that
the ‘very high’ responders had lower pain intensity than all other groups, and that
‘high’ responders had lower pain intensity than either the placebo patients or the
‘moderate’ responders.

Table 3; Figure 2 displays, by response group, pain

intensity through the average follow-up period of 21 months.
HbF response was also a significant predictor of analgesic use,
F(1,264)=27.52, p<.0001. The ‘very high’ responders had lower analgesic use
than all other groups; other pairwise differences were nonsignificant.
Similarly, HbF response significantly predicted utilization, F(1,264)=66.34,
p<.0001. The ‘very high’ and ‘high’ responders, who did not differ from each
other, had significantly lower utilization than the placebo patients or the other two
response groups, which did not significantly differ from each other.
Finally, the third set of models tested the three-group rather than the fivegroup hydroxyurea HbF response classification variable.

This HbF response

variable again significantly predicted pain intensity, F(1,264)=29.32, p<.0001.
Pairwise comparisons showed that the ‘higher’ response group had lower pain
intensity than either the ‘lower’ response or placebo groups, which did not differ
from each other.

Results for analgesic use were similar, F(1,264)=22.68,

p<.0001, with the ‘higher’ response group using analgesics less often than the
other two.

Finally, the three-group HbF response significantly predicted

utilization, F(1,264)=66.29, p<.0001, with the ‘higher’ response group reporting
significantly lower utilization than either the placebo or ‘lower’ response groups,
which did not differ.

Discussion
Our results used mixed models to show that in a randomized controlled
trial of hydroxyurea in sickle cell anemia, all three hydroxyurea daily symptomatic
pain response variables, constructed using data from a biweekly diary, differed
statistically significantly between the hydroxyurea and placebo groups, and
correlated with one another. Our results also subdivided patients by treatment
response based on quartiles of change in HbF in response to hydroxyurea, to
show that the hydroxyurea-related HbF response appears to drive the
hydroxyurea-related pain response.
These findings are an extension of our previous MSH study results, and
contrast with these results. Our first results showed that hydroxyurea treatment
was associated with a dramatic, statistically significant reduction in painful
crises.9 Later results showed a similarly dramatic reduction in mortality, in the
non-randomized MSH extension study.16 However, the reduction in the rate of
crises among hydroxyurea users was based on adjudication of crises by a board
of blinded investigators. A crisis was adjudicated if patients spent four or more
hours in a medical facility due to sickle cell pain.
Both the aims and results herein are different from those of prior analyses
of the MSH.

For this analysis, we instead focused on whether hydroxyurea

caused a reduction in daily pain intensity, in the proportion of days with analgesic
use, and in the proportion of days with utilization due to pain. Our observed
reductions were small compared to the minimal important difference (MID)xxiii, or
clinically significant difference on a Visual Analog Scale (VAS) in studies of acute
sickle cell pain and of post-operative pain(13 mm, or 13% change on a 100 mm
scale).xxiv

xxv

But we did not measure acute pain, nor did we use a VAS in this

study. Without studies that determine the MID for chronic pain in SCD using our
0-9 scale, we cannot say conclusively whether our observed differences in pain

intensity were clinically significant. However, for comparison, the differences we
found between groups were approximately 3-5% of the range from 0-9. Similarly,
we found 3-4% differences in analgesic use and utilization.
The meaning of the strong correlation between pain intensity and
analgesic use is open to several interpretations. We note that on most days, athome analgesic use was not reported. We suspect that the correlation indicates
that analgesics were not used on the days with no or minimal pain, and the
frequency of use simply increased as at-home pain levels increased.

The

correlations between analgesic use and utilization and between pain scores and
utilization raise hope that pain and analgesic use measures, with desirable
psychometric properties such as scalability, high frequency, and high resolution,
can be used as a measure of remittive drug effect in clinical trials of SCD. Using
these measures would obviate the need to conduct large, long, expensive
studies required to measure the rarer, correlated event, utilization, which is in
turn correlated with mortality. However, on most days the pain score was low,
though pain days were frequent, and opioid use frequent. Similarly, on most days
utilization did not occur, though there was pain. The correlations we observed
may thus be driven by no-utilization, no-pain days, or similar “no-no” days for the
other measures. Further, we believe that before these measures ultimately are
deemed useful in clinical trials of other chronic remittive SCD drugs or
analgesics, other testing must be done, including determining the MID of these
measures (see above) .
The differences in our three daily symptomatic pain response variables
between hydroxyurea and placebo patients occurred early, by six weeks of
therapy, paralleling the time course found previously in improvements in F cells
in MSH. Further, the daily symptomatic differences were each sustained during
the followup period, in a pattern that persisted through almost every month of
followup.

In addition, it is possible that the differences observed may be

conservative due to our methodology. As noted in the primary MSH paper, there
were periods off of hydroxyurea for the treatment group. This was not controlled
in our analyses, and it is possible that pain frequency and intensity increased for

the hydroxyurea group during these periods.

This would have the effect of

reducing differences in these outcomes between the treatment and placebo
groups.
When we examined the full four quartiles of hydroxyurea response
previously reported in MSH,12 results showed that the “very high” responders, in
particular, were driving the significant differences found. Not only did this group
have significantly lower scores on all pain response measures than the placebo
group, but it also had significantly lower pain intensity than both the “low” and
“moderate” response groups, and lower analgesic use and utilization than the
“moderate” response group.

The differences in averages between the “very

high” response group and the placebo group were larger: approximately 10-12%
on the 0-9 pain scale, 12% in daily probability of analgesic use, and 6% in daily
probability of a medical contact. For some, daily symptomatic response to HU
was no doubt dramatic. There were also inconsistent, smaller differences in the
three daily symptomatic response variables between “very high” response group
and the “high” HbF responders, or between either of these groups and the
“moderate” and “low” HbF responders or patients on placebo.
One explanation for our finding of small differences in analgesic use
between hydroxyurea vs. placebo groups is a possible “analgesia displacement
effect” resulting from avoidance of hospitalizations by use of hydroxyurea. MSH
showed that SCD patients using hydroxyurea are admitted less often to the
hospital. Hence, these patients stayed at home for a higher proportion of MSH
study time.

During these days, they may have taken analgesics for mild to

moderate pain.

Consequently their utilization of home analgesics may have

increased, and may not have been significantly different from patients not taking
hydroxyurea. Placebo patients may have taken large amounts of analgesics for
more severe pain, but over a shorter period of time.
Another explanation for some of our findings is that ambulatory pain
intensity ratings may exhibit a "ceiling effect" – days with higher pain ratings may
have been excluded because they met a threshold associated with a medical

visit. The effective range of pain ratings for ambulatory pain may have been 0-6
or 0-7, rather than 0-9. If this were true, our patients’ average ambulatory pain
response difference may well have been >5%.
We believe these results are vitally important, and in support of of a recent
NIH consensus statement on hydroxyurea in SCD.

xxvi xxvii

This statement

recommended wider, more consistent use of hydroxyurea in adults with SCD,
and possible use in children, but noted a problem with achieving effectiveness of
hydroxyurea--consistent adherence is required to demonstrate effectiveness.
The statement mentioned that 3 to 6 months of consistent treatment are required
for a clinical response to hydroxyurea, and that this delay decreases adherence.
Our results imply that decreased use of or adherence with hydroxyurea by SCD
patients and clinicians may be mainly due to lack of perceived effect on daily
symptomatic response: daily pain intensity, percent of days with analgesic use,
or percent of days with utilization. It is understandable that early, significant
improvement in pain is one benefit of hydroxyurea treatment that patents and
clinicians desire, and that they might begin or continue hydroxyurea therapy
based on this benefit.

Our results do suggest that any perceived daily

symptomatic benefits persist over time as therapy is continued.
However, our results, combined with earlier research, suggest that
clinicians and patients should make a final judgment about hydroxyurea benefit
based on whether there has been a positive HbF hydroxyurea response after
several months of therapy.9

Even when patients report no perceptible daily

symptomatic benefit of hydroxyurea, it would be unwise to discontinue
hydroxyurea without checking for a HbF response.

SCD mortality has been

related to the level of HbF in a dose-response fashion, as well as to frequency of
utilization.2

xxviii

Even small increases in HbF are beneficial to SCD mortality.2

Further, there is a statistically significantly higher HbF response to hydroxyurea
among patients who are ≥80% adherent overall, based on capsule counts at
study visits.12 All of these findings suggest discontinuation of hydroxyurea should

only be based on demonstration of no HbF response to hydroxyurea after a
several-month trial of therapy during which the patient is adherent.
On the other hand, our results suggest that clinicians may appropriately
accept early positive daily symptomatic responses to hydroxyurea as evidence of
a positive HbF hydroxyurea response. The results show that fetal hemoglobin
responsiveness to hydroxyurea, particularly very high responsiveness, may be
heralded by or correlated with a daily symptomatic response of reduced pain,
reduced analgesic use, and reduced utilization. For the fortunate circumstance
when patients show an early daily symptomatic response, clinicians may
reasonably conclude HbF responsiveness, or may choose to continue
hydroxyurea with less followup of HbF response (although regular measurements
of neutrophil, reticulocyte, and platelet counts are recommended to monitor for
bone marrow suppression). Future studies that identify patient characteristics
associated with HbF responsiveness may be of benefit in allowing physicians to
better predict the outcomes of hydroxyurea treatment.
Pain reduction is not the only indication for hydroxyurea treatment in sickle
cell anemia. Recent pediatric hydroxyurea studies have shown promise that
hydroxyurea can prevent organ damage in children,
xxxvii xxxviii
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.

Important limitations of the meaning of our findings are worth noting. First,
putting aside reductions in hospitalization for pain and in mortality among users
of hydroxyurea previously reported in MSH, the improvements in pain, analgesic
use, and utilization we report herein leave great room for improvement in
treatment of SCD pain.

Users of hydroxyurea still often require opioids for

palliation of acute and chronic SCD pain. Second, we studied a very select
population. Only patients with more than three hospitalizations per year were
included in MSH. Our results may not extrapolate to less severely ill SCD
patients. Also, MSH study participants were enrolled nearly 20 years ago, and
followed strenuous study procedures, including adherence with hydroxyurea, for
a mean follow-up of 21 months.

Differences in the availability of alternative

treatments and in patients’ motivation and social support may yield different
adherence and different outcomes in patients beginning hydroxyurea today.

Tables
Table 1. Demographics of the MSH sample (N=299)

Group

Sex:
Male
Female
Education:
Less than high school
High school/GED
Some college
B.A./postgraduate degree
Personal income:
Less than 10,000
10,000-19,999
20,000-29,999
30,000-39,999
40,000-49,999
Employment
Full-time
Part-time
Unemployed/disabled
Student (full or part-time)
Age at qualifying visit
Mean (standard deviation)
Range

Hydroxyurea
(n=152)
%

Placebo
(n=147)
%

49.3
48.3
50.7
51.7
Χ2(1)=0.033, p=.86
17.8
18.4
33.6
38.1
44.1
38.8
4.6
4.8
Χ2(3)=0.96, p=.81
65.3
73.3
20.4
18.5
7.5
3.4
4.8
3.4
2.0
1.4
Χ2(4)=3.53, p=.47
19.5
17.4
13.4
18.1
62.4
58.3
4.7
6.3
2
Χ (3)=1.70, p=.64
30.6 (7.54)
29.8 (7.47)
18-59
18-54
t(297)=0.93, p=.35

Table 2. Least squares means estimates and standard errors for hydroxyurea
daily symptomatic response variables, by model.
Model

Na

Hydroxyurea and
placebo
Placebo
146
Hydroxyurea
147
Overall p-value,
differences between
groups
HbF response (4
levels) and placebo
Placebo
146

Least Squares Means Estimate (Standard Error), by Daily
symptomatic Response Variable
Average pain
Proportion of
Proportion of
b
ratings
days with
days with
analgesic useb
utilizationb
2.82 (0.063)
0.44 (0.008)
0.11 (0.003)
2.51 (0.062)
0.40 (0.008)
0.08 (0.003)
p=.0007
p=.0006
p<.0001

2.82 (0.062)A

0.44 (0.008)A

0.11 (0.003)A

Low response

33

2.71 (0.134)AB

0.41 (0.018)A

0.10 (0.006)A

Moderate response

38

3.01 (0.122)A

0.45 (0.016)A

0.11 (0.006)A

High response

36

2.47 (0..126)B

0.42 (0.017)A

0.07 (0.006)B

Very high

34

1.85 (0..125)C

0.32 (0.017)B

0.05 (0.006)B

p<.0001
p<.0001
p<.0001
Overall p-value,
differences between
groups
Abbreviations: HbF= fetal hemoglobin.
a
Within each model, n’s for subgroups are consistent across the three daily
symptomatic response variables. 146 of 147 placebo patients and 147 of 152
hydroxyurea patients had data for the daily symptomatic response variables; 141
of 152 hydroxyurea patients had data on HbF response to treatment.
b
In the model incorporating HbF response, different uppercase superscripts
within a column (A,B,C) indicate that least squares means differ at p<.05 (e.g., in
the model for proportion of days with utilization, the placebo, low response, and
moderate response groups do not significantly differ from each other, but have a
significantly higher proportion of days with utilization than either the high or very
high groups, which in turn do not differ from each other).

Table 3. Statistical significance (p-values) for between-group comparisons, by
model and outcome
Groups

p-value

Placebo vs. ‘High’ responders
Placebo vs. ‘Very High’ responders
‘Low’ vs. ‘Very High’ responders
‘Moderate’ vs. ‘High’ responders
‘Moderate’ vs. ‘Very High’ responders
‘High’ vs. ‘Very High’ responders

p=.014
p<.0001
p<.0001
p=.003
p<.0001
p=.001

Placebo vs. ‘Very High’ responders
‘Low’ vs. ‘Very High’ responders
‘Moderate’ vs. ‘Very High’ responders
‘High’ vs. ‘Very High’ responders

p<.0001
p<.0001
p<.0001
p<.0001

Placebo vs. ‘High’ responders
Placebo vs. ‘Very High’ responders
‘Low’ vs. ‘High’ responders
‘Low’ vs. ‘Very High’ responders
‘Moderate’ vs. ‘High’ responders
‘Moderate’ vs. ‘Very High’ responders
Abbreviations: HbF=fetal hemoglobin.

p<.0001
p<.0001
p=.003
p<.0001
p<.0001
p<.0001

Model and outcome
HbF response (4
levels) and placebo
Average pain
intensity:

Proportion of days
with analgesic use:

Proportion of days
with utilization:

Figure 1.
Treatment group and average pain scores by visit, through week 90 (21 months)

Figure 2.
Treatment group and average pain scores by visit, through week 90 (21 months)
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